Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if CSE-MRI is as accurate as FLT PET in telling the difference between active and inactive marrow. The best way to do the comparison between the two imaging procedures is if they are done at the same time on the same patient. This is possible with use of a scanner at the University of Wisconsin Hospital

Trial Details

NCT ID
NCT07609225
Phase
EARLY_PHASE1
Sponsor
University of Wisconsin, Madison
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 3'-Deoxy-3'-[18F]-fluorothymidine
  • Chemical-shift-encoded MRI
Locations (sample)
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Ability to understand and the willingness to sign a written informed consent document.
  • Patients must be informed of the experimental nature of the study and its potential risks, and must sign institutional review board (IRB) approved …
  • Individuals at least 18 years of age.
  • Patients must have histologically or cytologically confirmed prostate cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →